Literature DB >> 12184502

Possible anxiolytic effects of ivermectin in rats.

H de Souza Spinosa1, S R A N Stilck, M M Bernardi.   

Abstract

Ivermectin, a mixture of 22,23-dihydroavermectin B1a (> or = 80%) and B1b (< or =20%), is produced by Streptomyces avermectilis, an actinomycete. It is a macrocyclic lactone disaccharide, a member of the avermectin family, and is used as an antiparasitic drug. Previous studies performed in our laboratory showed that doramectin, another avermectin drug, interferes with GABAergic-related behaviours, leading to anxiety and seizures. The objective of the present study was to examine the effects of ivermectin (0.5 and 1.0 mg/kg) on the central nervous system of rats, using behavioural models related to GABAergic neurotransmission. A known anxiolytic drug, diazepam, was used as a positive control. Open field and elevated plus-maze behaviours, as well as conflict behaviour to a conditioned response, were assessed. The effects of ivermectin and diazepam in reversing the anxiety induced by picrotoxin was studied. The protective effects of ivermectin on pentylenetetrazole- and picrotoxin-induced seizures were also investigated. In the open field, 1.0 mg/kg ivermectin decreased locomotion frequency at 15 and 60 min of observation, rearing behaviour showed a biphasic effect at 15 and 30 min and duration of immobility was increased in all sessions after 1.0 mg/kg ivermectin. These data suggest anxiolytic or sedative effects. Ivermectin and diazepam both had a tendency to cause an increase both in the number of entries into the open arms and on the time spent in the open arms of an elevated plus-maze. Picrotoxin on its own reduced the number of entries as well as the time spent in the open arms. Both diazepam and ivermectin reversed these effects of picrotoxin. In conflict behaviour analysis, ivermectin and diazepam gave the classic effect of an anxiolytic drug, reversing the conditioned response to shock. Ivermectin protected rats from the convulsant effects of pentylenetetrazole but not from those of picrotoxin. Thus, ivermectin had the pharmacological profile of an anxiolytic drug with GABAergic properties. The lack of effect on seizures induced by picrotoxin suggests that the action of ivermectin is different from that of the benzodiazepine drugs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12184502     DOI: 10.1023/a:1016094726033

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN: 0165-7380            Impact factor:   2.459


  39 in total

Review 1.  Inhibitory glutamate receptor channels.

Authors:  T A Cleland
Journal:  Mol Neurobiol       Date:  1996-10       Impact factor: 5.590

2.  Anxiolytic and anticonvulsant properties of doramectin in rats: behavioral and neurochemistric evaluations.

Authors:  H de Souza Spinosa; M Gerenutti; M M Bernardi
Journal:  Comp Biochem Physiol C Toxicol Pharmacol       Date:  2000-12       Impact factor: 3.228

3.  Impact of differential housing on humoral immunity following exposure to an acute stressor in rats.

Authors:  D R Baldwin; Z C Wilcox; R C Baylosis
Journal:  Physiol Behav       Date:  1995-04

4.  Anticonvulsant effects of avermectin in DBA/2 mice and rat.

Authors:  D Ammendola; A De Sarro; G B De Sarro; G Germanà; F Naccari; D Rotiroti
Journal:  Exp Biol       Date:  1988

5.  Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat.

Authors:  S Pellow; P Chopin; S E File; M Briley
Journal:  J Neurosci Methods       Date:  1985-08       Impact factor: 2.390

6.  A sensitive open field measure of anxiolytic drug activity.

Authors:  D R Britton; K T Britton
Journal:  Pharmacol Biochem Behav       Date:  1981-10       Impact factor: 3.533

7.  Ethological comparison of the effects of diazepam and acute/chronic imipramine on the behaviour of mice in the elevated plus-maze.

Authors:  J C Cole; R J Rodgers
Journal:  Pharmacol Biochem Behav       Date:  1995-11       Impact factor: 3.533

8.  Postsynaptic inhibition of invertebrate neuromuscular transmission by avermectin B1a.

Authors:  T N Mellin; R D Busch; C C Wang
Journal:  Neuropharmacology       Date:  1983-01       Impact factor: 5.250

9.  Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat.

Authors:  S Pellow; S E File
Journal:  Pharmacol Biochem Behav       Date:  1986-03       Impact factor: 3.533

10.  Raised corticosterone in the rat after exposure to the elevated plus-maze.

Authors:  S E File; H Zangrossi; F L Sanders; P S Mabbutt
Journal:  Psychopharmacology (Berl)       Date:  1994-01       Impact factor: 4.530

View more
  10 in total

1.  Analysis of genome-wide association data highlights candidates for drug repositioning in psychiatry.

Authors:  Hon-Cheong So; Carlos Kwan-Long Chau; Wan-To Chiu; Kin-Sang Ho; Cho-Pong Lo; Stephanie Ho-Yue Yim; Pak-Chung Sham
Journal:  Nat Neurosci       Date:  2017-08-14       Impact factor: 24.884

2.  Avermectins differentially affect ethanol intake and receptor function: implications for developing new therapeutics for alcohol use disorders.

Authors:  Liana Asatryan; Megan M Yardley; Sheraz Khoja; James R Trudell; Nhat Hyunh; Stan G Louie; Nicos A Petasis; Ronald L Alkana; Daryl L Davies
Journal:  Int J Neuropsychopharmacol       Date:  2014-01-22       Impact factor: 5.176

3.  Contribution of P2X4 receptors to ethanol intake in male C57BL/6 mice.

Authors:  Letisha R Wyatt; Deborah A Finn; Sheraz Khoja; Megan M Yardley; Liana Asatryan; Ronald L Alkana; Daryl L Davies
Journal:  Neurochem Res       Date:  2014-03-27       Impact factor: 3.996

4.  Preclinical development of moxidectin as a novel therapeutic for alcohol use disorder.

Authors:  Nhat Huynh; Natalie Arabian; Anna Naito; Stan Louie; Michael W Jakowec; Liana Asatryan; Daryl L Davies
Journal:  Neuropharmacology       Date:  2016-09-15       Impact factor: 5.250

Review 5.  Preclinical evaluation of avermectins as novel therapeutic agents for alcohol use disorders.

Authors:  Sheraz Khoja; Nhat Huynh; Alicia M P Warnecke; Liana Asatryan; Michael W Jakowec; Daryl L Davies
Journal:  Psychopharmacology (Berl)       Date:  2018-03-02       Impact factor: 4.530

6.  Ivermectin reduces alcohol intake and preference in mice.

Authors:  Megan M Yardley; Letisha Wyatt; Sheraz Khoja; Liana Asatryan; Marcia J Ramaker; Deborah A Finn; Ronald L Alkana; Nhat Huynh; Stan G Louie; Nicos A Petasis; Marco Bortolato; Daryl L Davies
Journal:  Neuropharmacology       Date:  2012-03-23       Impact factor: 5.250

7.  Pharmacologically targeting the P2rx4 gene on maintenance and reinstatement of alcohol self-administration in rats.

Authors:  Therese A Kosten
Journal:  Pharmacol Biochem Behav       Date:  2011-03-21       Impact factor: 3.533

8.  Pharmacological insights into the role of P2X4 receptors in behavioural regulation: lessons from ivermectin.

Authors:  Marco Bortolato; Megan M Yardley; Sheraz Khoja; Sean C Godar; Liana Asatryan; Deborah A Finn; Ronald L Alkana; Stan G Louie; Daryl L Davies
Journal:  Int J Neuropsychopharmacol       Date:  2012-09-17       Impact factor: 5.176

9.  Effects of the veterinary pharmaceutical ivermectin in indoor aquatic microcosms.

Authors:  Harry Boonstra; Erik P Reichman; Paul J van den Brink
Journal:  Arch Environ Contam Toxicol       Date:  2010-04-27       Impact factor: 2.804

Review 10.  P2X4 receptors (P2X4Rs) represent a novel target for the development of drugs to prevent and/or treat alcohol use disorders.

Authors:  Kelle M Franklin; Liana Asatryan; Michael W Jakowec; James R Trudell; Richard L Bell; Daryl L Davies
Journal:  Front Neurosci       Date:  2014-06-24       Impact factor: 4.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.